Enthusiasm doesn’t always lead to clear-eyed risk assessment or strategic usage plans, leaving companies vulnerable to ...
Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its tally of weight-loss candidates in clinical development to five. The massive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback